相似文献
1
Current Status of the GALAD and BALAD Biomarker Models for Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2019 Dec;15(12):672-675.
2
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
Clin Gastroenterol Hepatol. 2016 Jun;14(6):875-886.e6. doi: 10.1016/j.cgh.2015.12.042. Epub 2016 Jan 13.
3
The BALAD-2 and GALAD biomarker models for hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2017 Jun;15(6):452-454.
4
The BALAD-2 and GALAD Biomarker Models for Hepatocellular Carcinoma.
Gastroenterol Hepatol (N Y). 2017 Apr;13(4):231-233.
5
The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
Z Gastroenterol. 2016 Dec;54(12):1296-1305. doi: 10.1055/s-0042-119529. Epub 2016 Dec 9.
6
Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey.
J Gastroenterol. 2017 Oct;52(10):1112-1121. doi: 10.1007/s00535-017-1321-6. Epub 2017 Feb 21.
7
Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.
J Gastroenterol Hepatol. 2015 Oct;30(10):1529-35. doi: 10.1111/jgh.13005.
8
Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.
Oncology. 2008;75 Suppl 1:83-90. doi: 10.1159/000173428. Epub 2008 Dec 17.
9
[Validation of the diagnostic value of GALAD model in hepatocellular carcinoma patients].
Zhonghua Gan Zang Bing Za Zhi. 2018 Aug 20;26(8):621-623. doi: 10.3760/cma.j.issn.1007-3418.2018.08.012.
10
Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection.
Hepatol Res. 2016 Mar;46(3):E130-5. doi: 10.1111/hepr.12544. Epub 2015 Jul 6.
引用本文的文献
1
Serum-biomarker-based population screening model for hepatocellular carcinoma.
iScience. 2025 Feb 8;28(3):111981. doi: 10.1016/j.isci.2025.111981. eCollection 2025 Mar 21.
2
Plasma Insulin/Erythrocytic Aldose Reductase Ratio as a Predictor for Hepatocellular Carcinoma among Type II Diabetics and Hepatitis C Virus-infected Patients.
Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3815-3823. doi: 10.31557/APJCP.2022.23.11.3815.
3
Hepatocellular carcinoma surveillance: current practice and future directions.
Hepatoma Res. 2022;8. doi: 10.20517/2394-5079.2021.131. Epub 2022 Mar 11.
4
A Practical Model is Equivalent to the BALAD or BALAD-2 Score in Predicting Long-term Survival after Hepatectomy in Chinese Patients with Hepatocellular Carcinoma.
J Cancer. 2021 Jan 1;12(5):1474-1482. doi: 10.7150/jca.51593. eCollection 2021.
5
Epigenetic Associations between lncRNA/circRNA and miRNA in Hepatocellular Carcinoma.
Cancers (Basel). 2020 Sep 14;12(9):2622. doi: 10.3390/cancers12092622.
本文引用的文献
1
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score.
Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281. Epub 2018 Nov 21.
2
Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
World J Gastroenterol. 2018 Mar 28;24(12):1321-1331. doi: 10.3748/wjg.v24.i12.1321.
3
Should AFP (or any biomarkers) be used for HCC surveillance?
Curr Hepatol Rep. 2017 Jun;16(2):137-145. doi: 10.1007/s11901-017-0349-7. Epub 2017 Apr 28.
4
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Hepatology. 2003 May;37(5):1114-21. doi: 10.1053/jhep.2003.50195.
Zotero 插件